Sign Out
Hypersensitivity to fenofibrate or fenofibric acid or to any of the excipients of Colestrim Supra. Patients with severe renal impairment, including those receiving dialysis; active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities; preexisting gallbladder disease.
Use in lactation: Fenofibrate should not be used in nursing mothers.
145-mg: A decision should be made whether to discontinue nursing or to Colestrim Supra, taking into account the importance of Colestrim Supra to the mother.
160-mg: Because of the potential for tumorigenicity seen in animal studies, a decision should be made whether to discontinue nursing or to discontinue Colestrim.
